---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044006"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:41:46.012364+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in

## Summary
- Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.
- LP-300 Harmonic trial: 86% clinical benefit rate, 43% objective response in 7-patient lead-in; expanded to Japan and Taiwan.
- LP-184 Phase 1a: 9 cohorts dosed, no DLTs; FDA Fast Track for GBM; Phase 1b/2a expected early 2025.
- LP-284 Phase 1a: fourth cohort dosing, no DLTs; additional hematology sites planned; potential Phase 1b/2 by mid-2025.
- R&D expenses $3.7M (up from $2.2M); G&A $1.5M ($1.3M); 10.8M shares outstanding.

## SEC filing metadata
- accession: 0001493152-24-044006
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315224044006/0001493152-24-044006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315224044006/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044006
- JSON: https://secwatch.observer/filing/0001493152-24-044006.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.